摘要
目的了解盐酸埃克替尼在其耐药患者后续化疗中的疗效。方法回顾性分析盐酸埃克替尼耐药的46例晚期非小细胞肺癌(NSCLC)患者的临床资料,根据治疗方法的不同分为化疗组和联合组(化疗+埃克替尼),比较两组治疗效果。结果化疗组和联合组无进展生存期(PFS)、总生存期(OS)分别为5.7和6.9个月,19.4和18.7个月,两者比较差异无统计学意义(P>0.05)。两组客观有效率(ORR)分别为43.5%、34.8%,P值为0.546,两组疾病控制率(DCR)分别为86.9%,95.7%,P值为0.086,均无统计学意义。其中吸烟患者埃克替尼治疗PFS均值为5.8个月,不吸烟患者PFS为9.8个月,两者有统计学意义(P=0.01)。化疗组的疗效与吸烟及性别关系不大(P>0.05),联合组吸烟患者和不吸烟患者PFS、OS分别为4.8和8.3个月(P=0.004)、13.0和22.3个月(P=0.017),差异有统计学意义。联合组男性患者和女性患者PFS、OS分别为5.3和8.2个月(P=0.041)、13.7和22.5个月(P=0.023),差异有统计学意义。埃克替尼耐药后年龄和靶向治疗耐药时间长短对两种治疗方案疗效影响均不大。结论晚期非小细胞肺癌埃克替尼治疗耐药后继续埃克替尼联合化疗与单纯化疗疗效相仿,不吸烟及女性患者在耐药后继续埃克替尼联合化疗较吸烟及男性患者疗效更佳。
Objective To understand the efficacy of icotinib in the follow-up chemotlierapy of drug-resistantpatients. Methods The clinical data of 46 advanced NSCLC patients with icotinib resistance were retrospectively analyzed. Based on different therapies,all patients were divided into two groups,the chemotherapy groubining therapy group （ chemotherapy plus icotinib）. The effect of the two groups was compareand OS in the chemotlierapy group and the combining therapy group were 5.7 months VS. 6.9 months and 19.4 months VS. 18. 7 months,and there was no statistically significant difference between the two groups （P 〉0.05）. The ORRin the chemotherapy group and the combining therapy group were 43. 5% VS. 34. 8%,and the DCR in thetwo groups were 86. 9% VS. 95. 7% （ P 〉 0 .0 5 ） . The PFS in smoker and non-smoker of receiving the first icotinib treatment were 5. 8 months VS. 9. 8 months （ P = 0 .0 1 ） . There was not much to do witli curative effect of tile chemo-therapy group witli icotinib resistance and smoking or sex （ P 〉 0. 05 ）. The OS and PFS in non-smokers and smokersof the combining therapy group with icotinib resistance were 4. 8 months VS. 8. 3 months months VS. 22. 3 months （ P = 0. 0 1 7 ） . The OS and PFS in men and women of tlie combining therapy group witli icotinib resistance were 5. 3 months VS. 8. 2 months （ P = 0. 041 ） and 13. 7 months VS. 22. 5 months （ P = 0. 023 ）. There was not much to do with curative effect of the two treatments with icotinib for the first stage （ P 〉 0. 05 ） . Conclusion The effect of tlie AP chemotlierapy group and the icotinib ment group in advanced NSCLC patients is similar in the development of icotinib resistance in targeted therapy,and the efficacy in non-smokers and women are better than smokers and men in the icotinib plus AP treatment group.
出处
《临床肺科杂志》
2018年第3期406-410,共5页
Journal of Clinical Pulmonary Medicine
基金
安徽高等省级科学研究项目(No KJ2013A145)
